Cardiac arrest without evident cardiac disease may be caused by genetic conditions that are difficult to diagnose. Provocative testing to unmask a phenotype is often necessary to detect primary electrical disease, direct genetic testing, and perform family screening. Patients resuscitated from cardiac arrest that was unexplained after an initial evaluation showed normal left ventricular function and an absence of coronary artery disease underwent systematic testing that included advanced imaging and drug challenge. A diagnosis was obtained in 56% of patients. Key testing included magnetic resonance imaging to detect arrhythmogenic right ventricular cardiomyopathy and myocarditis, telemetry and ergonovine challenge to diagnose coronary spasm, and adrenaline/procainamide infusion to diagnose long-QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome. Targeted genetic testing demonstrated evidence of causative mutations in 47% of patients tested, which resulted in detection of disease in 24% of 64 family members screened. This systematic approach to clinical testing unmasked the cause of apparently unexplained cardiac arrest in the majority of patients. This clinical approach assists in directing genetic testing to confirm genetically mediated arrhythmia syndromes and facilitates directed family screening to identify at-risk family members. See p 278.
Spinal Cord Stimulation Improves Ventricular Function and Reduces Ventricular Arrhythmias in a Canine Postinfarction Heart Failure Model
Sudden cardiac arrest and heart failure (HF) are among the leading causes of morbidity and mortality in the industrialized world. The majority of pharmacological therapies available target symptoms or clinical manifestations rather than actually improve cardiac function. Implantable cardioverter-defibrillators and cardiac resynchronization therapy with defibrillation can improve survival but do not markedly improve cardiac function in the majority of patients receiving these therapies, and many patients progress to end-stage HF. At this point, therapeutic options to improve ventricular function include surgical placement of ventricular assist devices or cardiac transplantation. Cardiac transplantation is limited by the static supply of donor organs (currently 2500 to 3000 available per year). Importantly, the cost of these surgical treatments is high, and therefore they can only be offered to a small percentage of the patients who suffer from end-stage HF. This situation underscores the urgent need to develop novel and cost-effective therapies for the treatment of end-stage HF. The present work provides experimental evidence that neuromodulation using spinal cord stimulation (SCS) can significantly improve cardiac function and decrease the prevalence of lethal arrhythmias in a canine infarction and HF model. Because SCS is a less-invasive and morbid therapy than standard surgical options, it may prove to be a novel and effective therapeutic option in the HF patient. Clinical trials are obviously needed to evaluate the safety and efficacy of SCS in human heart failure. If SCS proves to be an effective therapy for human HF, a new treatment paradigm may emerge for this difficultto-treat patient population. See p 286.
Recurrence of Congenital Heart Defects in Families
The present study provides population-based estimates for familial recurrence risk ratios for the same congenital heart defect. Specific congenital heart defect phenotypes showed very strong familial clustering in first-degree relatives, ranging from 3-fold to 80-fold compared with the population prevalences of these heart defect phenotypes. The population-based recurrence risk ratios of the same heart defect phenotypes in the present study constitute familial clustering of nonsyndromic heart defects, whereas chromosomal and syndromic heart defects play only a small role in recurrent heart defects. The presence of increased crossover relative risks between dissimilar heart defects, although weaker, suggests that certain families have a susceptibility to heart defects. A first-degree family history of any heart defect accounts for only 2.2% of the heart defect cases in the population (4.2% when persons with chromosomal aberrations are excluded). Although recurrence risk ratios are strong, very few families experience a second heart defect of any type, which is important for clinical counseling. Because most heart defects occur as the only case in a family, a large proportion of heart defects presumably arise in susceptible individuals who carry lowpenetrance genes or gene combinations, possibly in interaction with maternal or intrauterine factors. See p 295.
Children and Adults With Congenital Heart Disease Lost to Follow-Up: Who and When?
Many patients with congenital heart disease require lifelong care. However, the proportions of patients who are lost to follow-up during childhood and early adulthood are not well described, nor are the risk factors for loss to follow-up. We used administrative databases in the province of Quebec, Canada, to describe outpatient cardiology follow-up among all persons born in 1983 and diagnosed with congenital heart disease before their sixth birthday. Subjects were followed until 22 years of age. Loss to follow-up was an important problem both within the pediatric age range and at the time of transition to adult care. Only 39% of the cohort saw a cardiologist between 18 and 22 years of age. Among those with severe lesions, only 79% were seen by a cardiologist in early adulthood. Reasons for loss to follow-up included male sex, having a nonsevere congenital heart disease lesion, and having previous cardiology care outside of a university hospital setting. The great majority of patients were still seeing primary care physicians, however, implying that there may be a lack of awareness about the need for follow-up cardiac care within the medical community. These findings have important implications for both pediatric and adult congenital cardiologists. Concerted efforts are required to contact children and families who do not attend clinic visits. Improved communication from cardiologists to primary care physicians about the potential for late cardiac complications and the need for long-term follow-up may help. Adolescents and their families require sufficient preparation for the transition to adult congenital heart disease healthcare settings. See p 302.
Neuregulin-1␤ Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
Neuregulin-1 (NRG-1) is a paracrine growth factor released from cardiac microvascular endothelial cells that acts via the ErbB family of tyrosine kinase receptors to regulate cardiomyocyte differentiation, growth, and stress responsiveness. Alteration of this pathway in animals induces heart failure, whereas peripheral administration of recombinant NRG-1␤ partially restores ventricular function and improves survival in animal models of cardiomyopathy. In humans, the chemotherapeutic agent trastuzumab, which inhibits the ErbB2
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Original Research Put Into Perspective for the Practicing Clinician Volume 120 Ⅲ Number 4 Ⅲ July 28, 2009 receptor, can induce a reversible cardiomyopathy as a toxic side effect, strongly suggesting that NRG-1/ErbB signaling is cardioprotective in the human heart. Here we provide the first study of endogenous circulating NRG-1␤ in human heart failure. We used a novel immunoassay to quantify circulating NRG-1␤ levels in 899 subjects in the Penn Heart Failure Study, a large referral cohort of patients with a broad spectrum of primarily systolic failure. We determined that increased levels of NRG-1␤ were independently associated with disease severity and risk of death or cardiac transplantation. Associations were independent of brain natriuretic peptide and were strongest in patients with ischemic heart failure and in patients with New York Heart Association class III/IV symptoms. Moreover, assessment NRG-1␤ and brain natriuretic peptide jointly improved risk stratification beyond assessment of each biomarker individually in these 2 subgroups. With further study, NRG-1␤ may be useful as part of a panel of biomarkers to assess prognosis in chronic heart failure. See p 310.
Loss of Cardiac Phosphoinositide 3-Kinase p110␣ Results in Contractile Dysfunction
Small molecule inhibitors of phosphatidylinositol 3-kinases are currently being tested in early clinical trials for treatment of cancer. These drugs inhibit all 4 phosphatidylinositol 3-kinase catalytic isoforms, including p110␣. Results from this study show that inhibition of p110␣ in cardiac myocytes reduces the ion current through the L-type Ca 2ϩ channel. Because the L-type Ca 2ϩ current regulates myocyte contraction, treating patients with cancer who have underlying heart problems with nonselective phosphatidylinositol 3-kinase inhibitors might lead to deleterious cardiac side effects. See p 318.
Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation: Results of the CARILLON Mitral Annuloplasty Device European Union Study
Functional mitral regurgitation is common in patients with heart failure and is associated with increased morbidity and mortality. However, its specific contribution to the heart failure syndrome and its progression is not completely understood. Despite the frequent occurrence of moderate to severe functional mitral regurgitation, surgery is rarely performed because of risk per se and the presence of major comorbidities. The impact of medical therapy on functional mitral regurgitation is variable. The CARILLON Mitral Annuloplasty Device European Union Study (AMADEUS) is a single-arm study designed to evaluate the safety and efficacy of a novel percutaneous mitral annuloplasty device. Thirty patients implanted with the device experienced significant improvements in functional capacity and quality of life with reduced mitral regurgitation over a 6-month follow-up period. This study supports the rationale for intervening on functional mitral regurgitation in heart failure patients with further evaluation in appropriate randomized studies. See p 326.
Active Adaptation of the Tethered Mitral Valve: Insights Into a Compensatory Mechanism for Functional Mitral Regurgitation
Mitral regurgitation is a frequent complication of myocardial infarction that doubles heart failure and mortality and is caused by stretch of the mitral leaflets by damaged and bulging heart walls preventing effective valve closure. Compensatory valve growth could reduce mitral regurgitation. A recent patient study showed significantly enlarged leaflets in patients with left ventricular dysfunction compared with normal subjects; whether the valve actively grows over time or is just passively stretched is unknown. The individual effects of ischemia, regurgitant jet flow, and leaflet stretch on potential valve adaptation, all present in ischemic MR, also are unknown. This study combined a new model producing isolated and controlled leaflet stretch with a noninvasive technique for quantifying valve area changes over time in an interdisciplinary collaboration with basic scientists. Two months of leaflet stretch by apical papillary muscle retraction reactivated embryonic development pathways, resulting in valvular and chordal growth shown by cellular activation, transformation of endothelial to interstitial cells, and new matrix deposition. Leaflet surface area and both leaflet and chordal thickness increased substantially relative to baseline and unstretched controls. The mitral valve therefore actively adapts in this setting. Understanding the mechanisms of such active adaptation can potentially provide therapeutic opportunities to augment MV area and reduce ischemic MR. See p 334.
